| 1 |
33376542 | Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells. | 2021 Feb |
1 |
| 2 |
34508613 | Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. | 2021 Sep 10 |
1 |
| 3 |
34608124 | Severe cellular stress activates apoptosis independently of p53 in osteosarcoma. | 2021 Oct 4 |
2 |
| 4 |
34622346 | Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics. | 2021 Oct 7 |
1 |
| 5 |
34837676 | AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines. | 2021 Oct |
1 |
| 6 |
32551032 | BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis. | 2020 |
1 |
| 7 |
33191863 | Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway. | 2020 Dec |
1 |
| 8 |
30535471 | MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. | 2019 Feb |
1 |
| 9 |
30929387 | [Effects of artesunate combined with bortezomib on apoptosis and autophagy of acute myeloid leukemia cells in vitro and its mechanism]. | 2019 Mar 14 |
1 |
| 10 |
31432126 | [Corrigendum] MicroRNA‑497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl‑2. | 2019 Oct |
1 |
| 11 |
28905994 | MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. | 2018 Jan 1 |
1 |
| 12 |
29057477 | The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs. | 2018 May |
1 |
| 13 |
30292410 | Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. | 2018 Nov 2 |
1 |
| 14 |
28000897 | Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma. | 2017 Feb |
1 |
| 15 |
28281027 | Proteasome inhibitors against amelanotic melanoma. | 2017 Dec |
1 |
| 16 |
28356941 | Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. | 2017 Feb |
2 |
| 17 |
28487980 | Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia. | 2017 Jul |
3 |
| 18 |
28964970 | Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. | 2017 Dec |
1 |
| 19 |
26657288 | Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. | 2016 Jan 19 |
1 |
| 20 |
26939706 | Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. | 2016 May |
2 |
| 21 |
27769058 | Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. | 2016 Nov 22 |
1 |
| 22 |
27822577 | Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. | 2016 Dec 20 |
1 |
| 23 |
27863383 | Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy. | 2016 Dec 27 |
1 |
| 24 |
25373508 | ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. | 2015 Jul |
1 |
| 25 |
25528518 | The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. | 2015 Feb 5 |
1 |
| 26 |
25602436 | Bortezomib inhibits gastric carcinoma HGC-27 cells through the phospho-Jun N-terminal kinase (p-JNK) pathway in vitro. | 2015 Apr 1 |
1 |
| 27 |
25714012 | Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. | 2015 Sep 29 |
2 |
| 28 |
25973303 | Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells. | 2015 |
1 |
| 29 |
25975837 | ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. | 2015 Sep |
1 |
| 30 |
25995634 | Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells. | 2015 |
1 |
| 31 |
26171069 | Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. | 2015 Jul |
3 |
| 32 |
26378933 | Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. | 2015 |
1 |
| 33 |
26472030 | Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells. | 2015 Nov 10 |
1 |
| 34 |
26544558 | Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis. | 2015 |
1 |
| 35 |
23697845 | Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. | 2014 Feb |
1 |
| 36 |
25120804 | Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. | 2014 |
2 |
| 37 |
23449448 | Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. | 2013 Feb 28 |
1 |
| 38 |
24086672 | JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. | 2013 |
1 |
| 39 |
24377552 | Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. | 2013 |
1 |
| 40 |
21993018 | Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. | 2012 Jan 1 |
1 |
| 41 |
22054286 | Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. | 2012 Jun |
4 |
| 42 |
22145750 | Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines. | 2012 Jun |
1 |
| 43 |
22559167 | Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. | 2012 May 4 |
1 |
| 44 |
22895144 | Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. | 2012 Sep |
1 |
| 45 |
21247388 | Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. | 2011 Mar |
2 |
| 46 |
21340723 | Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. | 2011 Aug |
1 |
| 47 |
21454712 | Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. | 2011 May 20 |
3 |
| 48 |
21459798 | Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. | 2011 May 15 |
1 |
| 49 |
21729550 | [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism]. | 2011 Jun |
1 |
| 50 |
22169296 | [Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol]. | 2011 Dec |
1 |